锕锕锕锕锕锕～再深点+在线观看,痛痛痛痛痛痛疼疼色板推特,天天碰天天爱天天摸,成人18毛片女人

您好，歡迎來到上海士研管理咨詢有限公司
產業(yè)峰會 演講局 專家智庫服務 峰會活動服務 整合營銷服務
  • 產業(yè)峰會：
    以專業(yè)團隊對產業(yè)和市場客觀詳實地調研為前提，擁有戰(zhàn)略性、系統(tǒng)性、全球性的基因，匯集了領導者關注的熱點話題與領袖代表，為您提供“一站式”的對話、分享、社交平臺!
  • 演講局：
    致力于為全球企業(yè)和機構提供主題演講家、高管大師班、董事會顧問，每項服務都提供了一種更深入、更具互動性的體驗，尤其是針對較小的精選受眾和關鍵個人。我們擁有最具影響力的商業(yè)領袖和頂級專家的資源，他們是各自領域的最杰出的代表。我們的團隊由經驗豐富的演講和活動經理組成，我們注重建立長期而深入的伙伴關系。
  • 專家智庫服務：
    中國領先的行業(yè)專家知識信息服務供應商，為需要專業(yè)洞見的商業(yè)決策者匹配具有一手經驗的行業(yè)專家，助力他們以更加明確的目標和堅定的信心做出決策。我們有60萬余名專家顧問遍布二十多個行業(yè)，而且每天還在增加！
  • 峰會活動服務：
    致力于成為全球最專業(yè)的產業(yè)峰會活動提供商，為企業(yè)和機構的產業(yè)性峰會活動提供一站式專業(yè)服務，包括調研策劃、定制邀請、營銷推廣、運營組織、項目管理、直播與數字化會議等，每項服務都由經驗豐富的專業(yè)團隊匹配長期沉淀的產業(yè)資源予以卓越執(zhí)行，我們注重建立長期而深入的伙伴關系。
  • 整合營銷服務：
    致力于成為全球領先的2B營銷服務機構，聚焦產業(yè)高端活動、內容、渠道的建設與沉淀，為客戶提供一站式整合營銷解決方案，助力企業(yè)線上線下獲客與品牌筑造。我們深信專業(yè)團隊匹配產業(yè)資源帶來卓越執(zhí)行，我們注重建立長期而深入的伙伴關系。
會議贊助商
4
2023 - 08 - 23
點擊次數:
泓博醫(yī)藥(股票代碼：301230)成立于2007年，總部位于上海，致力于為全球醫(yī)藥客戶提供新藥研發(fā)和商業(yè)化生產一站式綜合服務，涵蓋藥物發(fā)現、制藥工藝的研究開發(fā)以及原料藥、中間體的商業(yè)化生產等領域。目前，公司擁有超過22000平方米研發(fā)實驗室(37000平方米臨床前新藥研發(fā)基地在建中）以及60000平方米生產基地，研發(fā)技術人員占比超63%。在16年的征途中,泓博醫(yī)藥通過特有的“CRO”和“CDMO業(yè)務模式,構建了全方位綜合性技術平臺,為國內外客戶的新藥研發(fā)提供了有力支撐。 PharmaResources（StockCode：301230.SZ）was founded in 2007 and is headquartered in Shanghai. The company is committed to providing comprehensive services for global pharmaceutical clients, including new drug research and development and commercial production, covering areas such as drug discovery, pharmaceutical process research and development, as well as commercial production of active pharmaceutical ingredients and intermediates. Currently, the company has over 22,000 square meters of R&D laboratories (with a 37,000 square meter preclinical new drug R&D base under construction) and a 60,000 square meter production base. R&D technical personnel account for over 63% of the workforce. Over the course of its 16-year journey, PharmaResources has established a comprehensive technical platform through its unique 'CRO' and 'CDMO' business models, providing strong support for the new drug development of domestic and international clients.
5
2023 - 08 - 23
點擊次數:
藥明康德（股票代碼：603259.SH/2359.HK）為全球生物醫(yī)藥行業(yè)提供一體化、端到端的新藥研發(fā)和生產服務，在亞洲、歐洲、北美等地均設有運營基地。藥明康德通過獨特的“CRDMO”和“CTDMO”業(yè)務模式，不斷降低研發(fā)門檻，助力客戶提升研發(fā)效率，為患者帶來更多突破性的治療方案，服務范圍涵蓋化學藥研發(fā)和生產、生物學研究、臨床前測試和臨床試驗研發(fā)、細胞及基因療法研發(fā)、測試和生產等領域。2022年，藥明康德被MSCI評為ESG（環(huán)境、社會及管治）AA級。目前，公司的賦能平臺正承載著來自全球30多個國家的6000多家合作伙伴的研發(fā)創(chuàng)新項目，致力于將更多新藥、好藥帶給全球病患，早日實現“讓天下沒有難做的藥，難治的病”的愿景。As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the pharmaceutical and healthcare industry around the world to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, and cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2022 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that 'every drug can be made and every disease can be treated.'
6
2023 - 08 - 23
點擊次數:
太倉市沿江臨滬，地處沿海經濟帶和長三角經濟圈核心位置，距離上海張江藥谷和蘇州BioBAY均只需1小時車程，高鐵900秒抵達上海虹橋站，2027年地鐵接軌上海。太倉港是長江外貿第一大港，位列全球集裝箱港口第22位。太倉將生物醫(yī)藥作為重點發(fā)展的戰(zhàn)略性新興產業(yè)，圍繞新藥研發(fā)生產、醫(yī)療器械、醫(yī)藥服務外包等領域，已集聚了昭衍新藥、康乃德生物、中美冠科、含光微納、思納福、賽業(yè)模式生物、依科賽生物等400余家生物醫(yī)藥企業(yè)，形成了完善的上下游產業(yè)鏈。Taicang is not only borders Shanghai but also faces the Yangtze River, located in the core position of the coastal economic belt and the Yangtze River Delta economic circle. It is only about an one-hour drive both from Shanghai Zhangjiang Pharmaceutical Valley and Suzhou BioBAY and 900 seconds from Taicang railway station to Shanghai Hongqiao railway station. In additon, the subway will be connected to Shanghai in 2027. Taicang port is the largest foreign trade port on the Yangtze River and the 22th in the global container ports. Taicang prioritized Biomedical as a strategic industry, with a focus on new medical development and production, medical devices, and pharmaceutical outsourcing services. The biomedical industry has gathered nearly 400 biomedical enterprises in the city, including Joinn Laboratories, Connect Biopharmaceuticals, Crown Bioscience, HiComp Microtech, Sinafu Medical Technology, Cyagen Biosciences, ExCell Biotech and other potential biomedical enterprises, Already formed a complete industrial chain.
微信公眾號
領導者網絡APP
友情鏈接
Copyright ?2005 - 2017上海士研管理咨詢有限公司
犀牛云提供企業(yè)云服務